Drotrecogin alfa (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Drotrecogin alfa" in English language version.

refsWebsite

Global rank English rank

5web.archive.org

1^st place

5nih.gov

4^th place

4doi.org

2^nd place

1scientificamerican.com

896^th place

674^th place

1europa.eu

68^th place

117^th place

1businessweek.com

712^th place

526^th place

1lilly.com

low place

1medscape.com

719^th place

636^th place

1npr.org

92^nd place

72^nd place

1fda.gov

447^th place

338^th place

businessweek.com

Armstrong D (October 25, 2011). "Lilly Pulls Xigris Off Markets After Sepsis Drug Fails Study". Bloomberg BusinessWeek. Archived from the original on October 29, 2011.

doi.org

Martí-Carvajal AJ, Solà I, Gluud C, Lathyris D, Cardona AF (December 2012). "Human recombinant protein C for severe sepsis and septic shock in adult and paediatric patients". The Cochrane Database of Systematic Reviews. 2018 (12): CD004388. doi:10.1002/14651858.CD004388.pub6. PMC 6464614. PMID 23235609.
Eichacker PQ, Natanson C, Danner RL (October 2006). "Surviving sepsis--practice guidelines, marketing campaigns, and Eli Lilly". The New England Journal of Medicine. 355 (16): 1640–1642. doi:10.1056/NEJMp068197. PMID 17050887.
Warren HS, Suffredini AF, Eichacker PQ, Munford RS (September 2002). "Risks and benefits of activated protein C treatment for severe sepsis". The New England Journal of Medicine. 347 (13): 1027–1030. doi:10.1056/NEJMsb020574. PMID 12324562.
Angus DC, van der Poll T (August 2013). "Severe sepsis and septic shock". The New England Journal of Medicine. 369 (9): 840–851. doi:10.1056/NEJMra1208623. PMID 23984731.

europa.eu

ema.europa.eu

"Xigris (drotrecogin alfa (activated)) to be withdrawn due to lack of efficacy". Press release. London, UK: European Medicines Agency. 25 October 2011. Archived from the original on 28 October 2011. Retrieved 26 October 2011.

fda.gov

"FDA Drug Safety Communication: Voluntary market withdrawal of Xigris [drotrecogin alfa (activated)] due to failure to show a survival benefit". fda.gov. U.S. Department of Health and Human Services. October 25, 2011. Retrieved May 24, 2017.

lilly.com

"Eli Lilly Annual Report, 2001" (PDF). Archived from the original (PDF) on 2007-02-26. Retrieved 2008-08-17.

medscape.com

Barclay L (2002-10-01). "Controversy Brews Over Xigris' Role in Treating Sepsis". Medscape Medical News. WebMD LLC. Archived from the original on 2002-10-15. Retrieved 2010-09-19.

nih.gov

pubmed.ncbi.nlm.nih.gov

Martí-Carvajal AJ, Solà I, Gluud C, Lathyris D, Cardona AF (December 2012). "Human recombinant protein C for severe sepsis and septic shock in adult and paediatric patients". The Cochrane Database of Systematic Reviews. 2018 (12): CD004388. doi:10.1002/14651858.CD004388.pub6. PMC 6464614. PMID 23235609.
Eichacker PQ, Natanson C, Danner RL (October 2006). "Surviving sepsis--practice guidelines, marketing campaigns, and Eli Lilly". The New England Journal of Medicine. 355 (16): 1640–1642. doi:10.1056/NEJMp068197. PMID 17050887.
Warren HS, Suffredini AF, Eichacker PQ, Munford RS (September 2002). "Risks and benefits of activated protein C treatment for severe sepsis". The New England Journal of Medicine. 347 (13): 1027–1030. doi:10.1056/NEJMsb020574. PMID 12324562.
Angus DC, van der Poll T (August 2013). "Severe sepsis and septic shock". The New England Journal of Medicine. 369 (9): 840–851. doi:10.1056/NEJMra1208623. PMID 23984731.

ncbi.nlm.nih.gov

Martí-Carvajal AJ, Solà I, Gluud C, Lathyris D, Cardona AF (December 2012). "Human recombinant protein C for severe sepsis and septic shock in adult and paediatric patients". The Cochrane Database of Systematic Reviews. 2018 (12): CD004388. doi:10.1002/14651858.CD004388.pub6. PMC 6464614. PMID 23235609.

npr.org

Knox R (2006-10-18). "Report: Lilly Promoted Drug Under False Pretenses". All Things Considered. National Public Radio. Archived from the original on 2006-10-19. Retrieved 2010-09-19.

scientificamerican.com

blogs.scientificamerican.com

"Lilly's Shocker, or the Post-Marketing Blues". guest blog. Scientific American.

web.archive.org

"Xigris (drotrecogin alfa (activated)) to be withdrawn due to lack of efficacy". Press release. London, UK: European Medicines Agency. 25 October 2011. Archived from the original on 28 October 2011. Retrieved 26 October 2011.
Armstrong D (October 25, 2011). "Lilly Pulls Xigris Off Markets After Sepsis Drug Fails Study". Bloomberg BusinessWeek. Archived from the original on October 29, 2011.
"Eli Lilly Annual Report, 2001" (PDF). Archived from the original (PDF) on 2007-02-26. Retrieved 2008-08-17.
Barclay L (2002-10-01). "Controversy Brews Over Xigris' Role in Treating Sepsis". Medscape Medical News. WebMD LLC. Archived from the original on 2002-10-15. Retrieved 2010-09-19.
Knox R (2006-10-18). "Report: Lilly Promoted Drug Under False Pretenses". All Things Considered. National Public Radio. Archived from the original on 2006-10-19. Retrieved 2010-09-19.